22 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
26363867	2	¿(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system.	Universit£
23489211	44	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.	Universit£
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
18077363	314	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.	University of Oxford
16460940	13	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.	Hoffmann-La Roche
15953730	13	RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.	Hoffmann-La Roche
22014550	337	Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).	Ansaris
21958547	108	Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.	Pfizer
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
19783434	31	Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors.	Harvard Medical School
19788238	36	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).	University of Zurich
19035792	85	Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.	Glaxosmithkline
17303421	56	Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.	Roche Research Center
32292555	44	Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.	University of Oxford
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
31693351	473	Discovery of 4	TBA
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
9650799	159	[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.	Novartis Pharma